InsiderTrades.com logo
Mary B. Cranston net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Mary Cranston Biography and Net Worth

Director of MyoKardia
Mary B. Cranston is a retired senior partner of Pillsbury Winthrop Shaw Pittman LLP, an international law firm. She was the chair and chief executive officer of Pillsbury from January 1999 until April 2006, and continued to serve as chair of the firm until December 2006. She was Firm senior partner until January 2012. Ms. Cranston serves on the boards of directors of TPG and the Chemours Company. She previously served as a member of the boards of International Rectifier Corporation until January 2015, Juniper Networks, Inc. until May 2015, MyoKardia until November 2020, and McAfee until March 2022. Ms. Cranston holds an A.B. degree in Political Science from Stanford University, a J.D. from Stanford Law School, and an M.A. in Educational Psychology from the University of California, Los Angeles.

What is Mary B. Cranston's net worth?

The estimated net worth of Mary B. Cranston is at least $83,441.61 as of June 30th, 2020. Ms. Cranston owns 371 shares of MyoKardia stock worth more than $83,442 as of May 2nd. This net worth approximation does not reflect any other assets that Ms. Cranston may own. Learn More about Mary B. Cranston's net worth.

How do I contact Mary B. Cranston?

The corporate mailing address for Ms. Cranston and other MyoKardia executives is 1000 SIERRA POINT PARKWAY, BRISBANE CA, 94005. MyoKardia can also be reached via phone at 650-741-0900 and via email at ir@myokardia.com. Learn More on Mary B. Cranston's contact information.

Has Mary B. Cranston been buying or selling shares of MyoKardia?

Mary B. Cranston has not been actively trading shares of MyoKardia during the past quarter. Most recently, Mary B. Cranston sold 21,629 shares of the business's stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $96.60, for a transaction totalling $2,089,361.40. Following the completion of the sale, the director now directly owns 371 shares of the company's stock, valued at $35,838.60. Learn More on Mary B. Cranston's trading history.

Who are MyoKardia's active insiders?

MyoKardia's insider roster includes Mary Cranston (Director), and Tassos Gianakakos (CEO). Learn More on MyoKardia's active insiders.

Mary B. Cranston Insider Trading History at MyoKardia

See Full Table

Mary B. Cranston Buying and Selling Activity at MyoKardia

This chart shows Mary B Cranston's buying and selling at MyoKardia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2$0Total Insider BuyingTotal Insider Selling

MyoKardia Company Overview

MyoKardia logo
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $224.91
Low: $224.91
High: $224.91

50 Day Range

MA: $224.61
Low: $222.81
High: $224.91

2 Week Range

Now: $224.91
Low: $42.65
High: $225.00

Volume

N/A

Average Volume

752,969 shs

Market Capitalization

$11.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84